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INT R O D U C TI O N
INTR O D U CTIO N
Anemia is defined by world health organisation as hemoglobin levels <11gm/dl. It is 
one  of  the  most  serious  global  public  health  problem affects  52% of  pregnant  women in 
developing and 23% in developed countries (Cochrane data review).
In  under  developed  countries  anemia  is  a  major  contributory  factor  to  maternal 
morbidity, mortality and higher perinatal mortality rate.
Anemia in pregnancy is associated with an increased risk of preterm delivery, low-birth 
weight and maternal mortality (Harvey LJ – Dainty JR, Hollands WJ, et al).
Iron is an essential component of Hb (ie Oxygen carrying pigment in the Blood). The 
pregnant women needs 1000mg of iron all through pregnancy i-e 3.5 mg / day to maintain iron 
balance.  This  demand during  later  half  of  pregnancy and for  several  weeks  after  delivery 
increases to about 6.7 mg/day.
Iron is essential to life because of its unique ability to serve as both an electron donor 
and acceptor. 
In order to identify anemia in pregnancy, an accurate method for measuring Hb level is 
needed, many clinics in developing countries especially those in sub-saharan Africa, rely only 
on conjunctival inspections. 
WHO colour  scale might  still  be useful  especially  at  primary  health  care  level  as  a 
screening tool despite observed limitations in accuracy. The routine measurement of serum 
ferritin, the best indicator of body iron stores than Hb concentration is unrealistic for most of 
the low-income groups. 
(Who reproductive health library; Geneva ; WHO).
Various forms of Oral, intramuscular and intravenous preparations of iron have been 
used to correct iron deficiency anemia in pregnancy and puerperium. But they are associated 
with significant side effects  and not possible to achieve target  raise in Hb level  in limited 
period.
Although the best method of treating anemia has not been clarified, oral treatment is in 
theory the most feasible to use. But side effects of oral iron or women’s dislike of the tablets 
owing to smell or taste have been blamed for treatment failure.
(walraven G,and  candio F, treatments for iron deficiency anemia in pregnancy)
Mostly anecdotal evidence suggests that I.V and I.M iron administration is associated 
with  allergic  reactions.  Compared  with  I.M  iron,  I.V.  iron  sucrose  significantly  increased 
hematological indices with less side effects. 
(Cochrane Database syst Rev, 2006 ; 3; CD004736)
Iron  sucrose  complex  is  a  newer  drug  used  intravenously  for  correction  of  iron 
deficiency anemia with less side effects and able to raise the Hb to satisfactory level.
This was the study comparing the effectiveness, tolerability and safety of the two drugs 
intravenous iron sucrose and intramuscular iron dextran in the treatment of iron deficiency 
anemia in pregnant and postpartum women.
AI M  O F  T H E  ST U D Y  
AI M  O F  T H E  ST U D Y
1. To determine the efficacy, tolerability of intravenous iron sucrose in the treatment of 
iron deficiency anemia during pregnancy and    postpartum compared to intramuscular 
iron dextran. 
   2. To determine the safety of intravenous iron sucrose in the treatment of 
iron deficiency anemia during pregnancy and postpartum compared to intramuscular 
iron dextran.
R E VIE W    O F  LIT E R A T U R E  
R E VIE W  O F  LITE R AT U R E
Al Momen et al conducted a prospective, open-label controlled trial in 111  pregnant 
women with iron deficiency anemia (Hb : <9gm/dl) and divided into 2 groups. Intravenous 
group  (N.  55)  and  intramuscular  group.  Intravenous  iron  sucrose  was  administered  as  an 
infusion of single 100mg dose in normal saline every 1 to 3 days.
Controls received I.M iron dextran (100mg on alternate days) till the calculated dose 
was reached. Intravenous iron therapy resulted in higher levels of Hb, with the time to achieve 
maximum Hb in shorter period compared with controls. No serious adverse effects were noted 
in iron sucrose group whereas 6% of patients could not tolerate I.M iron dextran, who excluded 
from the study. 30% of patients in the control group had disturbing G1 symptoms and 32% 
were non complaint.
Wali A, MushtaqA, Nilofer.
(Journal Pakistan med. Assoc. 2002 sep 52(9) : 392 – 5)
A prospective comparative study, total number of 60 pregnant women with gestational 
age of 12 – 34 wks with iron deficiency were included, and divided into 2 groups. Group A (N: 
30) received intra venous iron sucrose according to recommended dose containing 500mg of 
iron sucrose for storage, Group B (n=30) received intramuscular iron dextran. Mean Hb in 
group A was 8.0+/- 1.1gm/dl and in group B was 8.8+/- 0.9gm/dl. In group A and B initial Hb 
was assesed 3 weeks after therapy which showed an average rise of 2.8gm/dl in group A and 
1.4 gm/dl group B. Target Hb level of 11gm/dl was achieved in 80% of group A, 28% of group 
B  patients.  In  group  A  one  patient  had  moderate  abdominal  pain,  2  had  weakness  and 
shivering, 3 had phlebitis  but none of the patients discontinued the therapy due to adverse 
effects.  In  group  B  majority  complained  of  pain  at  the  injection  site,  in  which  5  patients 
dropped  out  from study  due  to  intolerance.  They  concluded  that  I.V  iron  therapy  is  safe, 
convenient and more effective than I.M iron therapy, hence I.V iron therapy can replace blood 
transfusion in antenatal period.  
Bhandal .N. Russell. R carried out an prospective randomised trial enrolling 44 women 
with  iron  deficiency  anemia,  defined  as  Hb  <  9gm/dl  when  measured  24  to  48  hrs  after 
delivery. Group A received (N.22) 200mg I.V on days 2 and 4. Group B (N. 22) received 
200mg of oral ferrous sulphate twice a day for 6 wks. Average rise in Hb was 2.5gm/dl on day 
5 in I.V group and 0.7gm/dl in oral group. There were no serious adverse effects in I.V group 
except a few who reported facial flushing and metallic taste during iron infusion. 1/3 of women 
in oral group had gastrointestinal side effects. They concluded that in women with postpartum 
iron deficiency anemia intravenous iron sucrose produces higher blood Hb level than oral iron 
supplementation. 
Breyman et al conducted an prospective randomised open study evaluated the efficacy 
and safety of intravenous iron sucrose with or with out recombinant human erythropoietin in 
correcting iron deficiency anemia (Hb <10gm/dl) in pregnant women ie. gestational age (> 21 
weeks). 20 patients received recombinant human erythropoietin 300 IU/kg and iron sucrose 
200mg I.V and 20 patients received I.V iron sucrose 200mg alone twice weekly for 4 weeks till 
a  target  Hb  of  11  gm/dl  was  achieved.  There  was  immediate  reticulocyte  response  and 
progressive rise in hematocrit  in both groups.  Higher rise in reticulocyte count and rise in 
hematocrit was observed in the group that received combination therapy. None required blood 
transfusion. No serious adverse effects were reported. They concluded that I.V iron sucrose 
alone  should  be  considered  first  in  resistant  iron  deficiency  anemia  during  pregnancy. 
Recombinant  human  erythropoietin  may  be  considered  in  severe  anemia  requiring  rapid 
correction , not responding to I.V iron sucrose.
Lippincott Williams and Wilkins Inc, Pakistan institute of medical science conducted an 
randomised controlled study in 80 patients with gestational age of 12 – 36 wks from antenatal 
clinic and 20 patients after postpartum hemorrhage with anemia. Group A received I.V. iron 
sucrose, group B received I.M iron sorbitol. Group A had mean Hb content of 1.3 + 1.1 gm/dl 
and group B had 7.9 + 0.9 gm/dl .3 weeks post therapy assesment of Hb showed a total rise of 
2.6 gm/dl (Group A) and 1.2 gm/dl (Group B). Target Hb i.e 11gm/dl was achieved in 80% of 
group A and 20% of group B Patients. Blood transfusion was not required in any group. They 
concluded that I.V Iron sucrose is safe, convenient and more effective than I.M iron therapy in 
treatment of Iron deficiency anemia during pregnancy. It can minimise blood transfusion in 
postnatal women.
Scoff B. Silverstein and George Rodgers 
The increased availability of parentral iron preparation should decrease the need to use 
red cell transfusion in patients with iron deficiency anemia.
Sal-Momen Ak, al-Mechari A; al-Nuaime L et al in 1996 conducted an study comparing 
I.V iron sucrose  and oral  ferrous  sulphate,  they observed that  iron sucrose complex group 
achieved significantly  higher  Hb level  (128.5+/-  6.6gm/dl  Vs 111.4 +/-  12.4g/l)  in  control 
group. P < or = 0.001. Iron sucrose complex showed no major side effects, but 6% of control 
group could not tolerate ferrous sulphate. 30% had poor complaince in the control group. They 
concluded that iron sucrose complex is safe and effective in the treatment of iron deficiency 
anemia during pregnancy.
Catherine Gay (2005) concluded that although oral iron is the standard treatment for iron 
deficiency anemia, it is poorly tolerated and has low efficacy in rapid correction of anemia, But 
I.V iron sucrose is both quick and effective in treating anemia. The average mean rise of Hb 
was 0.8 gm/dl for oral iron, 3.5 gm/dl for blood transfusion and 3.1gm/dl for I.V iron after 14 
days. No serious adverse effects were noted for I.V iron sucrose.
Bayoumeu F, Subiran – Buisset E, Baka NE et al (2002) American Journal of obst. and 
Gynaecology  also  observed  the  effectiveness,  safety  and  tolerability  of  I.V  iron  sucrose 
compared to oral iron for treatment of iron deficiency anemia in pregnant women. 
Chamate E. conducted a study on treatment of iron deficiency anemia in pregnancy and 
immediate puerperium comparing I.V iron sucrose and oral ferrors sulphate and concluded that 
I.V iron sucrose is safe, convenient and more effective with less adverse effects and it can 
replace blood transfusion in antenatal period.
Al-Wakeel Js, Malik GH, Atmohaya S, et al 1997, also confirmed the effectiveness of 
intravenous iron sucrose in patients with iron deficiency anemia.
Baskin E, Besbas S, Bakkaloglu et al (1999) studied the effect of I.V iron sucrose in 
hemodialysed children. 
Silverberg Ds, Lania A, Peeg G et al (1996), studied the effectiveness, tolerability and 
safety of I.V iron sucrose for the treatment of anemia of moderate to severe chronic renal 
failure patients not receiving dialysis. 
Gravier A, Descargues G, Marpeace L et al (1999) conducted a study on how to avoid 
postpartum blood transfusions in  Iron deficiency anemia patients,  by treating with I.V.Iron 
sucrose.  They concluded that  I.V.Iron sucrose is  effective in preventing unnecessary blood 
transfusions in postpartum patients.
Scott B, Silverstein and George M et al (2004) they have observed that increase in Hb 
first noted after 1 week of iron sucrose administration and serious anaphylactic hypersensitivity 
0.002% in I.V iron sucrose group compared to 0.6 – 0.7% in I.M  iron dextran group.
Westad S,  Backe B,  Smedvig E et  al  studied the  effect  of  intravenous iron sucrose 
compared with oral ferrous sulphate, they concluded that women who received I.V iron sucrose 
replenished their iron stores more rapidly and had more symptomatic relief compared to oral 
iron. 
IR O N  M E T A B O LIS M  
IRO N  M E T A B O LIS M
Iron
Most of the iron in the diet is in the ferric (fe3+) form, where as it is the ferrous (Fe 2+) 
form that is absorbed. Fe 3+ will be converted into Fe2+ by Fe3+ reductase in the brush border of 
enterocytes (William F. Ganong 21st Edition).
Sources and Contents of Iron
Milk : Human Milk 0.5 mg
(litre) Cow’s milk 0.02 – 0.3 mg
Foods : a) Pulses (9 – 11mg)
(80 – 100gms)     Cereals ( 4 – 11mg)
b) Meat, Fish (10 - 25mg)
c) Ripe Banana (0.9mg)
    Mango (1.3 mg)  
    Melon (7.5 mg)
Iron is important is human body because of its occurance in many hematopoietins such 
as  hemoglobin,  myoglobin  &  cytochromes.  Digested  in  diet  as  heme  or  non  heme  iron. 
(Harper’s illustrated Biochemistry – 26th Edition).
Iron Absorption
Normally  greater  proportion  of  Dietary  heme  iron  than  non-heme  iron  is  absorbed 
reflecting the Greater importance of heme as source of iron.
(B Jorn Ramussen et al 1974).
Almost  all  iron absorption occurs in the duodenum. Iron absorption is  facilitated by 
reducing substances like ascorbic acid, Amino acids.
Sugars  especially  fructose  increases  the  absorption  and  may  contribute  to  dietary 
hemosiderin of bantus, who consume a diet high in sugar. (Forth and Rummel 1973)
Iron absorption is inhibited by alkalies,  phosphates,  phytates (maize, wheat),  also by 
mucosal block i.e., gut has a mechanism to prevent entry of excess iron in the body.
Daily iron requirement for menstruating adult female and pregnancy (last 2 trimesters) is 
1-2mg and 3-5mg respectively.
Good mixed diet provides 10 to 15 mg of iron/day. Normal absorption of 10% or so is 
enough to replace the loss but not able to replace the extra demands of body growth. (Harper’s 
illustrated Biochemistry – 26th Edi).
IRON TRANSPORT  
Ferrous  iron  is  transported  into  enterocyte  by  the  apical  membrane  iron  transporter 
DMT1.  Some form of ferrous iron is stored as ferritin and the remainder is transported out of 
the enterocytes by basolateral transporter ferroportin I. In the plasma ferrous iron  is converted 
to ferric form and bound to transferrin. Normally transferrin is about 35% saturated with iron.
Heme is transported into the enterocyte by separate heme transporter (HT), and heme 
oxidase releases Fe2+ from the heme. Some of the Fe2+ is converted to Fe3+ and bound to ferritin. 
The rest binds to Basolateral Fe2+  transporter ferroportin (FP), and bound to transferrin and 
stored in the body as ferritin and hemosiderin. 
Ferritin containing cells are exfoliated from the mucosal surface at the end of 2-3days 
life span. (Conrad and Barton 1981)
Transferrin does not cross the placenta but gives up its iron in chorionic villus, Iron is 
transferred across the placenta against steep concentration Gradient, so it is Enzyme dependent. 
(Waller Stein 1973)
The plasma transferrin is less than that expected from TIBC. (Vander Heul et al 1972)
In pregnancy this lack of correlation applies even to low transferrin saturation levels. 
(Charg and Sivasamboo 1973)
STRUCTURE OF HEME :
Heme group  consists  of  Protoporphyrin  IX linked to  an  atom of  further  coordinate 
valence bonds, one attached to polypeptide chain and the other for oxygen transport.
First  step  is  condensation  of  glycine  with  succinate,  this  is  iron  dependent. 
Protoporphyrin IX synthesis is inhibited by iron deficiency. (Ganong 21st Edition)
E R Y T H R O P O I E S I S  
E R YT H R O P OIESIS
Red blood cells production and destruction are balanced to maintain Hb concentration at 
normal levels.  Red blood cell  production is a dynamic process and anemia is  a  disordered 
dynamic process. (Dr. Ivor Cavill 6th Congress of European Society of Gynaecology 2005)
Decrease in Hb concentration due to various reasons causes decrease in  arterial oxygen 
carrying  capacity,  which  leads  to  increased  Erythropoietin  productions  in  kidney  which 
stimulated Erythropoiesis.
The  reliability  of  invitro  bioassay  is  dependent  on  compensating  for  the  modifying 
influences  of  other  human  serum  components  on  erythropoietin  activity  when  invitro 
procedures are employed to measure erythropoietin in serum. (Dekerk et al 1978. Firkin and 
Russel 1983)
Pleuripotent stem cell
Committed stem cells 
(Progenitor cell)
GM – CSF erythroid series
Pro erythroblast
Rapid division
Basophilic normoblast
Polychromatic normoblast
(Proliferation activity ceases after this stage. Begins to produce Hb in the cell. They are 
called intermediate normoblast).
Orthochromatic normoblast.
(Final  stage  of  maturation  of  nucleated  red  blood  cells.  Active  Hb  synthesis  occurs  in 
cytoplasm.
Active extrusion of nucleus.
Reticulocyte 
(Biconcave discoid shaped, greater volume and diameter than mature red blood cells)
Loss their mitochondria and ribosomes over the course of few days, loss the basophilic 
tint.
Mature erythrocytes.
Transfusion of blood sufficient to raise the hemoglobin concentration above normal or 
prolonged  inhalation  of  elevated  partial  pressure  of  oxygen  results  in  depression  of 
erythropoiesis  in  keeping  with  the  expected  consequences  of  such  feed  back  system  on 
regulation. (Lawrence et al 1952) 
Anemia  in  hypothyroidism  is  caused  by  hemodilution  due  to  expansion  of  plasma 
volume, although some decrease does occur in erythropoietic activity.
(FINCH et al 1970).
IRO N  D E FICIE N CY A N E MI A
Iron  deficiency  anemia  of  the  most  common  nutritional  deficiency  in  pregnancy 
followed by folate deficiency anemia. Out of 150 million deliveries occuring annually in the 
world, approximately 6,00,000 women die from the complications of pregnancy. Anemia is 
responsible for 40-60% of maternal deaths in non-industrialized countries. Anemic mother is 
more likely to succumb to the ill effects of hemorrhage, be susceptible to infection and suffer 
from congestive cardiac failure.  
(Progress in obstet and gynaecol, STUDD volume 15).
WHO criteria for diagnosis of anemia in pregnancy is Hb content of < 11 gm/dl. (7.45 
mmol/l) and hematocrit of less than 0.33. CDC  (Centers for Disease control, USA) proposes a 
cut off point of 10.5 gm/dl during the Second Trimester.
(Progress in obstet and gynaecol, STUDD  volume 15).
ICMR categories of anemia. (Progress in OBG, STUDD volume 15)
Category Severity Hb level (gm/dl)
1. Mild 10.0 - 10.9
2. Moderate 7.0 - 10.0
3. Severe < 7.0
4. Very severe < 4.0
IRON  DEFICIENCY ANEMIA;
Prevalence of anemia in pregnancy
Anemia affects about 18% of women during pregnancy in industrialised countries while 
in  non-industrialised  countries  prevalence  varies  between  35-75%  average  being  56%. 
Incidence of anemia in India ranges between 20 and 30% in the middle income group and 
much  higher in low income group(60%) and 70% in rural women. 
(Progress in OBG, STUDD  volume 15)
Iron Requirements in Pregnancy
Basal iron                            -          280mg,
Expansion of red cell mass - 570mg
Transfer to the fetus - 200-350 mg
Placenta - 50-150 mg
Blood loss at delivery - 100-250 mg 
After deducting iron conserved by amenorrhoea (240-480 mg) an additional 500-600 mg 
of  iron is  required in pregnancy or  4 – 6 mg/day of  absorbed iron i.e  2.5mg/day in  early 
pregnancy, 5.5mg/day from weeks 20 – 32 and 6 – 8 mg/day from weeks 32 onwards).
As absorption is less than 10% atleast 40 - 60mg of iron should be available in the diet.
Causes of high prevalence of Iron deficiency anemia;
1. Increased iron requirement 
2. Dietary habits 
Consumption of low bio availability diet, also higher in both Hindu vegetarian and Muslim 
(Halal Meat eaters), this could be due to loss of significant amounts of heme blood from the 
Halal meat where the animal is slaughtered by cutting its carotid artery and bled to death.
(Sharma and Soni 1999).
3. Defective iron absorption due to intestinal infection like hook worm, schistosomiasis, 
chronic malaria.
4. Menorrhagia / Bleeding from the gut due to haemorrhoids. 
Stages of Iron deficiency anemia;
Stage I : Negative iron balance
Demands for iron exceed the body ability to absorb iron from diet.
Normal Hb / hematocrit level
Normal RBC indices
           Serum .Ferritin < 20ng/ml
Stage II : Iron deficient Erythropoiesis
When stores become depleted serum iron begins to fall, total iron binding capacity rises 
gradually and once the transferrin falls to 15 to 20%, Hb synthesis becomes impaired. 
Stage III : Iron deficiency anemia
Peripheral picture reveals microcytic and hypochromic cells appearing as vacuolated red 
blood  cells  with  reticulocytes  in  circulation.  Gradually  Hb  and  hematocrit  begins  to  fall. 
Transferrin saturation< 15%.
Clinical Features
Patient  may be  asymptomatic  especially  in  mild  and moderate  anemia.  Patient  may 
complain  of  weakness,  exhaustion,  lassitude,  indigestion,  loss  of  appetite,  palpitation, 
dyspnoea, giddiness and edema. Congestive cardiac failure can occur in severe cases. 
Signs:
There may be no signs especially in mild anemia. There may be Pallor, glossitis and 
stomatitis. Patient may have edema due to hypoproteinemia. Soft systolic murmur can be heard 
in mitral area due to hyperdynamic circulation. There can be fine crepitations at bases of lungs 
due to congestion. 
Effects of anemia on pregnancy
Maternal effects
Mild anemia may not have any effect on pregnancy and labour except that the mother 
who has low iron stores, may become moderate to severely anemic in subsequent pregnancies. 
Moderate anemia may cause increased incidence of preterm labour  (28.2%), Pre-eclampsia 
(31.2%) and sepsis.  
During labour there is an increased incidence of postpartum hemorrhage and congestive 
cardiac failure.
During  puerperium there  is  an  increased chance of  puerperal  sepsis,  sub  involution, 
failing lactation and venous thrombosis.
Fetal effects
Irrespective of maternal iron stores, fetus tends to obtain iron from maternal transferrin. 
But gradually the fetal iron stores becomes depleted. So Baby’s born to anemic mother should 
be started on oral iron in the infancy itself.
Iron deficiency anemia is a significant risk factor for prematurity and Low birthweight 
infants if it is present in first trimester. In 2nd and 3rd trimester it had little effect on these fetal 
outcomes. (School et al).
Lozoff  et  al  observed a significant  effect  of  anemia on the affective behavior  of  an 
anemic child. 
Diagnosis
Although the assessment of iron status in human population is advanced compared with 
other nutrients, there is still a large uncertainty about absolute diagnosis during pregnancy. (Am 
J Clin Nutr. 1994 : 59 (Suppl) 5025 – 10s).
Parameters Normal -ve iron balance Iron deficient 
erythropoiesis
Iron 
deficiency 
anemia
Marrow iron stores 1 – 3 + 0 – 1 + 0 0
Serum ferritin(ng/ml) 50 – 200 < 20 < 15 < 15
TIBC (mg/dl) 300 – 360 > 360 > 380 > 400
Serum iron (mg/dl) 50 – 150 normal <50 < 30
Saturation (%) 30 – 50 normal < 20 < 10
Marrow sideroblasts (%) 40 – 60 normal < 10 <10
RBC  protoporphyrin 
(mg/dl)
30 – 50 normal >100 >200
RBC morphology normal normal normal Microcytic 
hypochromic
Red cell indices
MCV is the first to get reduced and is the most sensitive indicator of iron deficiency 
anemia. MCHC is reduced in more severe cases of iron depletion.           
 Normal        Iron deficiency anemia
MCV (fl) 75.96 reduced
MCHC (g/dl) 32.35 reduced 
Lipshitz  et  al  showed  that  for  each  grade  of  marrow  iron,  the  serum  ferritin 
concentration were 3 times higher in patients with infection than in control subjects. Thus the 
absolute  cutoff  of  12  –  15  mg/l  may  not  include  iron  deficiency  in  individuals  with 
inflammation.
Skikne et al showed that the serum transferrin receptor is a sensitive index of tissue iron 
deficiency and is relatively unaffected by inflammation or stage of pregnancy.
Prophylactic Supplementation
WHO recommendation based on the prevalence of anemia 
< 40% : 60mg elemental iron and 0.4mg of folic acid.
> 40% : supplemented for another 3 months postpartum.
National nutritional anemia control programme guidelines.
100mg of elemental iron and 0.5mg of folic acid for minimum of 100 days, starting in 
the 2nd trimester and continued 3 months postpartum. 
Schultink  et  al  observed  that  <50%  of  the  women  who  said  they  were  taking  the 
supplements  and  who  knew  they  would  be  tested  for  a  response  actually  did  take  their 
supplements as proved by iron positive stools.
Treatment of iron deficiency anemia
Iron deficiency aemia is the main cause of anemia during pregnancy. Iron should be the 
mainstay of therapy oral, parentral or through transfusion. 
Breymann 2005 explained that the efficacy of oral and intramuscular iron is limited in 
many patients due to dose dependent side effects, lack of compliance and insufficient duodenal 
iron absorption, and correction of hematological and iron status parameters are still lacking.
Breymann 2005 also stated that transfusion has many problems including transmission 
of viruses and bacteria, RBC quality can be compromised during storage and the possibility of 
transmitting prions is an increasing worry. 
Breymann  2005  maintained  that  following  I.V  iron  sucrose  administration  it  is  not 
necessary to survey the patient (or) monitor their blood pressure, the patient can leave with 
100% compliance.
The increased availability of multiple parenteral iron preparations should decrease the 
need to use red cell transfusions in patients with Iron deficiency anemia. (Am. J.  Hematol 76 : 
76 – 78, 2004).
P H A R M A C O L O G Y  O F  
INTR A V E N O US  IRO N  S UC R OS E
Iron Sucrose
Chemical Formula
[Na2 Fe5O8 (OH) 3 (H2o)]n . m(C12 H22 O11)
Iron sucrose is a brown, sterile, aqueous complex of polynuclear iron (III) hydroxide in 
sucrose containing 20mg elemental iron per ml.
The sterile solution has an osmolarity of 1250 mosm/l. The product does not contain 
preservatives. 
Molecular wt : 34,000 – 60,000 daltons 
PH                   : 10.5 – 11.1
Mechanism of action
Following intravenous administration, it is dissociated into iron and sucrose by reticulo 
endothelial system and iron is transferred from the blood into pool of iron in the liver and bone 
marrow. Ferritin sequester iron in a nonionic form  from which iron is easily available. 
Pharmacokinetics ;
Its iron component exhibits first order kinetics
Elimination t ½ : 6 hrs
Total clearance : 1.2 litres / hour
Non – steady state apparent volume of distribution : 10 lit
Steady state apparent volume of distribution : 7.9 lit.
Distribution
In healthy adults, its iron component appears to distribute mainly in blood and to some 
extent in extra cellular fluid. 
Elimination
The sucrose component is eliminated mainly by urinary excretion. Some iron is also 
eliminated in the urine. (approximately 5%)
Side effects
Headache, fever, pain, asthenia, malaise, abdominal pain.
Interaction 
Should  not  be  administered  concomitantly  with  oral  iron  preparation  since  the 
absorption of oral iron may be reduced.
Contraindications 
1. Evidence of iron over load.
2. Anemia not caused by iron deficiency 
3. Known hypersensitivity to I.V iron sucrose (or) any of its inactive compounds.
Method and route of administration
No test dose is required
1. Slow IV injection
100mg (2amp) to be given undiluted over a period of 2 – 5 min.
2. Slow IV infusion
100mg (2amp) to be diluted with 100ml of normal saline immediately prior to infusion 
and to be infused over a period of atleast 15min (6mg/min).
Dosage frequency
100mg/day given on alternate days until the required dose is infused.
Chandler et al observed that optimal doses of 200 – 300mg infused intravenously over 2 
hrs were well tolerated and safe. Patients who received doses of 400 – 500mg intravenously 
over 2 hrs experienced hypotension, nausea, and low back pain. 
Supply and storage
Supplied in 2.5ml single dose vial. Each 2.5ml vial contains 50mg of elemental iron 
(20mg/ml),  that  is  packaged  in  carton  containing  10  single  dose  vials.  Stored  at  250C. 
Excursions permitted to 15 – 300C.
Pharmacology of Intramuscular 
Iron Dextran
Iron  dextran  is  a  dark  brown slightly  viscous  sterile  liquid  of  ferric  hydroxide  and 
dextran, containing 50mg of elemental iron per ml. 
Molecular Weight : 165,000 g/mmol
PH : 5.2 to 6.5
Mechanism of action
Following  intramuscular  administration  it  is  absorbed into  capillaries  and  lymphatic 
system and the circulating iron is removed from the plasma by reticulo endothelial system, 
which split the complex into iron and dextran. 
Iron is bound to available protein moieties to form hemosiderin or Ferritin.
Encouraging results were  obtained only with low molecular weight dextran. I.M iron 
preparations has been made which is well absorbed with low toxicity.             (Fletcher and 
London 1954).
Elimination 
Dextran, a poly glucose which is either metabolised or excreted. Only negligible amount 
is lost via urinary / alimentary pathway but major portion is absorbed in 72hours. 
Side effects
Severe / fatal             :       Anaphylactic reactions
Cardiovascular system         :         Chest pain, hypotension, shock.
Dermatological         :         Urticaria, pruritis, purpural rash
Hematological : leucocytosis / lymphadenopathy
Neurological : Convulsions, seizure, headache.
Delayed : Arthralgia, backache, chills ,fever, 
Headache, myalgia.
Precautions
H/o significant allergy / asthma.
Oral iron should be discontinued prior to administration.
Supply and storage
Supplied as 50mg of elemental iron per ml in 2ml single dose amber vials in cartons of 
10 which is  stored at 20 – 250C (68 – 670F).
Iron dextran does not precipitate with change of pH, therefore buffering action of blood 
does not affect its stability.
(Cappell 1930 and Nission 1935)
Method and Route of Administration
Test dose : 0.5ml is given in the same recommended site and by the 
same technique. Although anaphylactic reactions known to occur, which 
usually  evident  in  few min.  It  is  recommended that  atleast  an  hour  or 
longer elapse before the remainder of the therapeutic dose is given. 
100mg of elemental iron (2ml) is given as deep intramuscular injection into the upper 
outer quadrant of the buttock using a Z technique .(Pulling the skin and subcutaneous tissue to 
one side before inserting the needle).
M A T E RI A LS A N D  M E T H O D S
M A T E RIA LS A N D  M E T H O DS
This  prospective  randomised  controlled  study  was  undertaken at  Government  Rajaji 
Hospital attached to Madurai Medical College in obstetrics and Gynaecological department. 50 
antenatal patients with gestational age between 28 – 34 wks attending antenatal OPD and 50 
postnatal patients with iron deficiency anemia (Hemoglobin between              7 – 9gm/dl) were 
selected which includes both booked and unbooked cases.
Inclusion Criteria for the Patients
Following criterias were utilised in selecting patients for this study
1. Age 18 – 45 yrs
2. Singleton  pregnancy between 28 to 34 wks
3. Hb < 11gm/dl or hematocrit < 33%.
Exclusion Criteria    
1. Underlying disease such as hypertension, gestational diabetes, heart   
      disease, peptic ulcer. 
    2. H/o allergy to iron containing medication.
    3. H/o other allergic conditions or asthma.
    4. Thalassemia.
    5. H/o Bleeding tendency.
    6. H/o blood transfusion with in prior 120 days.
After confirming iron deficiency anemia using peripheral smear,  antenatal and postnatal 
patients  with  iron  deficiency  anemia  who  fulfilled  the  above  said  criteria  were  randomly 
allocated into 2 groups. Group A and group B. Group A contains 25 antenatal and 25 postnatal 
patients and group B contains 25 antenatal and 25 postnatal patients. 
After  obtaining  an  informed  consent,  a  detailed  history  taking  and  complete  general 
examination and detailed obstetric examination were done. 
METHOD OF THE STUDY
Calculation of iron requirement 
Iron requirement is calculated using the following formula 
Antenatal patients ;
2.4 x (target Hb – patient Hb) x 
pre pregnancy Weight (kg) + 500 (Storage iron) =        mg
No need for test dose.
Group A patients were given intravenous iron sucrose complex, 100mg of elemental iron 
diluted in 100ml of 0.9% normal saline was infused over 15min daily until the required dose 
was infused. 
Group B patients were given intramuscular iron dextran 100mg [lamp contains 2ml] as 
deep  intramuscular  injection  into  the  upper  outer  quadrant  of  buttock  using  Z  technique’. 
(Pulling the skin and subcutaneous tissue to one side before inserting the needle).
Additional precautions were taken to prevent even a slight drop of solution to come 
beneath the skin surface by injecting small quantity of air or Saline down the needle before 
withdrawing it. Given daily until the required dose was infused.
Observations
During therapy the following parameters were monitored 
1. Vitals (Pulse, BP, Temperature)
2. Adverse effects like nausea / vomitting / abdominal pain, chills etc.
3. Anaphylactic reactions.
The following investigations were done before therapy to asses the degree of anemia.
1. Hb
2. Hematocrit.
3. MCV
Patients  were  advised  to  attend  our  OPD  3  weeks  after  therapy  and  the  following 
parameters were assesed.
1. Symptomatic improvement
2. Hb
3. Hematocrit.
4. MCV
R ES U L TS
O BS E R V ATIO NS A N D  R ES U LTS
This study was conducted in 100 patients (50 antenatal and 50 postnatal patients) and 
they were  randomly allocated into 2 groups.  Group A and group B.  Group A contains 25 
antenatal  and 25 postnatal  patients.         Group B contains 25 antenatal and 25 postnatal 
patients.
Group A : Received intravenous iron sucrose 100mg per day diluted  
in 100ml of 0.9%  normal saline  till the required dose was infused.
Group B : Received I.M iron dextran 100mg per day deep I.M in  
gluteal region till the required dose was infused.
CHARACTERISTICS OF CASES STUDIED
Table 1
Age distribution
Age Group
Intravenous 
Group
Intramuscular 
Group
No % No %
Total %
Less than 20 years 4 8 11 22 15
21 – 25 years 31 62 18 36 49
26-30 years 12 24 12 24 24
Above 30 years 4 8 8 16 12
Total 50 100 50 100 100
Mean
S.D
24.62
4.2
25.0
5.07
‘p’ 0.9779 Not Significant
There were no significant difference among the groups regarding age distribution as 
shown in table 1 
Among  100  women  studied,  15%  (15/100)  were  less  than  20yrs,  49% (49/100)  of 
patients belongs to the age group. 21 – 25yrs, 24% (24/100) belongs to age group 26 – 30yrs, 
12%  belongs  to  age  >30yrs.  The  mean  age  was  24.62  and  25  in  group  A  and  group  B 
respectively.
AGE DISTRIBUTION
49
12
15
24
Upto 20 years 21-25 yrs 26-30 yrs Above 30 yrs
Table 2
Booking Status
Booking Status
Intravenous 
Group
Intramuscular 
Group
Total
No. % No. % %
Booked 12 24 14 28 26
Unbooked 38 76 36 72 74
‘p’ 0.8197
Not significant
Among the 100 women studied 74% were unbooked, 26% were booked.  Booked and 
unbooked cases were equally distributed in 2 groups. 
           Among  the  50 patients  in group A  12/50 (24%)  were booked, 38/50 (76%) were 
unbooked.  In group B 14/50 (28%)  were  booked and 36/50 (72%) were unbooked.
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Table 3
Socio economic Status
Socio economic 
Status
Intravenous
Group
Intramuscular 
Group
Total
No. % No. % %
Class I - - - - -
Class II - - - - -
Class III 4 8 8 16 12
Class IV 46 92 42 84 88
‘p’ 0.3559
Not significant
 88% of women belonged to class IV socioeconomic status. 12% belonged to class III 
Socio economic class. None of the patients belonged to class I and class II group.
          Among  50 patients in group A 4/50 (8%) belonged to class III  and 46/50 (92%) 
belonged to class IV socio economic status .In group B 8/50 (16%) belonged to class III and 
42/50 (84%) belonged to class IV group.
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Table 4
Parity
Parity
Intravenous
Group
Intramuscular 
Group
Total
No. % No. % %
Primi 18 36 18 36 36
Multi 32 64 32 64 64
Among the 100 women studied 36% were primipara 64% were multipara, 64% were 
para 2 and above. Both primi and multipara were equally distributed in both groups.
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Table 5
Symptoms
Symptoms
Intravenous
Group
Intramuscular 
Group
Total
No. % No. % %
Asymptomatic 36 72 28 56 64
Easy fatiguability 10 20 12 24 22
Breathlessness (GradeI) 6 12 8 16 14
Pallor of skin & 
Mucous membrane
16 32 10 20 26
Menstrual problems 3 6 4 8 7
Among the 100 women studied 64 patients (64%) were asymptomatic, 22% presented 
with easy fatiguability, 14% with Breathlessness (Grade I), 7% with menstrual problems, and 
26% patients showed pallor of skin and mucous membrane.  
Table 6
Symptomatic well being (improvement)
Symptoms
Intravenous
Group
Intramuscular 
Group
No. % No. % ‘p’
Easy fatiguability 10/10 100 3/12 25 0.0015
Significant
Breathlessness 5/6 83.3 4/8 12.5 0.0163
Significant
Pallor 16/16 100 4/10 10 0.0001
Significant
Among 10 patients with easy fatiguability and 6 patients with Breathlessness (Grade I) 
and 16 patients with pallor, all (100%) experienced improvement of symptoms after treatment, 
whereas  in  iron  dextran  group  among  12  cases  with  easy  fatiguability  and  8  cases  with 
breathlessness (Grade I) only 3/12 cases and 4/8 cases respectively experienced improvement 
of  symptoms.  Thus  statistically  significant  difference  of  improvement  in  symptoms  in 
intravenous  group  when  compared  to  intramuscular  group.  P  value  showed   statistically 
significant difference.
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Table 7
Change in Hb.%
Hb.%
Intravenous
Group
Intramuscular 
Group
Mean S.D Mean S.D
‘p’
Before treatment 7.88 0.51 7.86 0.43 0.7619
Not significant
After treatment 10.84 0.56 9.19 0.36 0.0001
Significant
Change in Hb.% 2.97 0.55 1.36 0.35 0.0001
Significant
Mean Hb in group A and group B was 7.88 gm/dl and 7.86 gm/dl respectively. Post 
therapy  Hb  after  3  weeks  showed  an  mean  Hb  value  of  10.84%  gm/dl  and  9.19  gm/dl 
respectively (P value : 0.001), which was statistically significant. The average rise of Hb was 
2.97 gm/dl and 1.36 gm/dl respectively (P value 0.001), which was statistically significant. 
Target Hb was achieved in 80% of group A, 20% of group B patients.
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Table 8
Change in Hematocrit
Hematocrit
Intravenous
Group
Intramuscular 
Group
Mean S.D Mean S.D
‘p’
Before treatment 30 2.5 31.4 1.7 0.9619
Not significant
After treatment 41.3 4.7 36.8 1.9 0.0342
Significant
Change in 
Hematocrit
11.3 2.8 5.4 1.3 0.0001
Significant
Among 100 patients  studied,  hematocrit  in Group A and Group B was 30 and 31.4 
respectively. Post therapy hematocrit after 3 weeks showed an mean hematocrit value of 41.3 
and 36.8 respectively. P value is 0.0342, which was statistically significant and the average rise 
of hematocrit was 11.3 and 5.4 in group A & B respectively, which was statistically significant.
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Table 9
Change in MCV
MCV
Intravenous
Group
Intramuscular 
Group
Mean S.D Mean S.D
‘p’
Before treatment 68.2 6.3 66.6 4.7 0.7619
Not significant
After treatment 83.9 5.8 74.8 6.1 0.0023
Significant
Change in MCV 15.6 6.7 8.2 5.5 0.0001
Significant
Among 100 patients studied, mean MCV in group A and group B was 68.27 fl and 66.6 
fl respectively. Post therapy assesment after 3 weeks in group A and group B showed as mean 
MCV  value  of  83.9  fl  and  74.8fl  respectively,  (P  value  0.0023)  which  was  statistically 
significant  and  the  average  rise  in  MCV was  15.7  fl  and  8.2fl  in  group  A  and  group  B 
respectively.  
CHANGE IN MCV
68.2
83.915.6
66.6
74.8
8.2
0 10 20 30 40 50 60 70 80 90 100IN
TR
AV
EN
O
U
S
G
R
O
U
P
IN
TR
AM
U
SC
U
LA
R
G
R
O
U
P
Before treatment After treatment Increase
Table 10
Adverse effects of the drug
Adverse effects of the drug
Intravenous
Group
Intramuscular 
Group
No. % No. %
Headache 2 4 4 8
Nausea/ Vomitting - - - -
Abdominal pain 1 2 6 12
Chills/rigors 4 8 12 24
Joint pain        - - 32 64
Anaphylactic 
reaction(Hypotension)
- - - -
Thrombophlebitis 1 2 - -
Pain at the injection site - - 38 76
Patients with adverse effects 8 16 38 76
Patients without adverse effects 42 84 12 24
‘p’ 0.0001
Significant
Among the 50 patients in group A side effects were minimal(16%)  like headache 2/50 
(4%) abdominal pain 1/50 (2%), chills & rigors 4/50 (8%) Thrombophlebitis (2%) and more 
side effects 38% like joint pain 32/50(64%) ,pain at the injection site 38/50 (76%), chills / 
rigors 12/50 (24%) and abdominal pain 6/50 (12%) were found in group B. But there was no 
anaphylactic  reactions  noted  in  both  groups  P  value  is  0.0001.  Adverse  reactions  were 
statistically significant between two groups.   
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Table 11
Complaince
   
Complaince
Intravenous
Group
Intramuscular 
Group
No. % No. %
Discontinued treatment due to 
adverse effects
Nil - 10/50 20
Not come for follow up 4/50 8 8/40 20
  
Among 50 patients in intravenous group none of the patients discontinued the treatment 
due to adverse effects, where as in intramuscular group among 50 patients 10 patients 10/50, 
discontinued the treatment due to adverse effects.
Among 50 patients in intravenous group 4 cases 4/50 (8%) did not come for follow up, 
where as in intramuscular group 8 patients 8/40 (20%) did not come for follow up.
Statistical Tools 
The information collected regarding all the selected cases were recorded in a Master 
Chart. Data analysis was done with the help of computer using Epidemiological Information 
Package (EPI 2002).
Using this  software, frequencies,  percentages,  means,  standard deviations,  chi  square 
and ‘p’ values were calculated. Kruskul Wallis chi-square test was used to test the significance 
of difference between quantitative variables and Yate’s  test  for  qualitative variables.  A ‘p’ 
value less than 0.05 is taken to denote significant relationship.
DIS C USSI O N
DISC USSIO N
In this study 100 patients (50 antenatal and 50 postnatal) with iron deficiency anemia 
were selected according to the inclusion and exclusion criteria stated in methodology. They 
were divided into 2 groups (50 patients each).
In group A, patients were given injection intravenous iron sucrose 100mg I.V. infusion 
per day until the calculated dose was infused.
In group B, patients were given injection intramuscular iron Dextran 100mg I.M. per 
day until the calculated dose was infused.
The distribution of patients as per Age, Parity, Booking Status and Socioeconomic status 
were equal in 2 groups, so that the results can be predicted with accuracy.
In our study 16% (16/100) of the patients were upto 20yrs. 49% (49/100) of the patients 
were in the age group of 21 – 25 yrs. 23% (23/100) of the patients were in the age group of 26 
– 20yrs and 12% (12/100) of the patients were > 30yrs.
In our study 74% of the patients were unbooked and 26% were booked. Booked and 
unbooked cases were equally distributed in 2 groups. .
In  our  study  84% of  women belonged to  class  IV socio  economic  status  and 16% 
belonged to class III socioeconomic status. Majority were in low socio economic group.
In our study 32% of the patients were primipara and 68% were multipara. Majority were 
in multipara group.
In our study 64% were asymptomatic,  22% presented with easy   fatiguability,  14% 
presented with breathlessness (Grade I), 10% presented with menstrual problems. 26% showed 
pallor of skin and mucous membrane. Thus 64% of patients were asymptomatic in our study.
In  our  study  all  patients  (100%)  were  experienced  symptomatic  well  being  in 
intravenous group, when compared to intramuscular group in which among 12 cases with easy 
fatiguability and 8 cases with breathlessness (Grade I) only 3 cases and 4 cases respectively 
were experienced improvement of symptoms.
    
 P value is 0.0001. Thus statistically significant difference observed between 2 groups.
Comparison of outcome parameters
Changes in Hemoglobin:
In our study, hemoglobin level was measured before treatment and again after 3 weeks 
post therapy assesment was done using sahli’s hemoglobinometer at GRH laboratory. 
Mean Hb in group A and group B was 7.88% and 7.86%, respectively. Post therapy Hb 
after 3 weeks showed an mean Hb value of 10.84 gm% and 9.19gm% respectively. P value is 
0.001 which was statistically significant.
An average  rise  in  Hb  was  2.97  gm% and  1.36  gm% (p  value  0.001),  which  was 
statistically significant and target Hb was achieved in 80% of women in group A and 20 % of 
women in  group  B.
According  to  study  by  Walia  et  al  J  Pak  med  Assoc.  2002  Sep;  a  prospective 
comparative study included a total number of 40 pregnant women with gestational age of 12 – 
34 weeks showed a mean hemoglobin in group A and group B was 8.0 +/- 1.1 gm% and 8.8 +/- 
0.9 gm% respectively, post therapy Hb after 3 weeks showed an average rise of 2.8 gm% in 
group A and 1.4 gm in group B. Target Hb (11 gm/dl) was achieved in 80% in group A and 
28% in group B patients. Our study was comparable with above mentioned study.
Our study was comparable with study by Ann Pak Inst.  med sci.  Sep 2006; Zahana 
hospital attached and Hashmi maternity clinic Dera Ismail Khan, a randomised controlled study 
showed a total  rise of 2.6gm% in group A and 1.2gm% in group B.  Target  Hb level  was 
achieved in 80% of group A and 20% of group B patients.
Another study by Bayoumeu et al,  American Journal of Obstetrics and Gynaecology 
March 2002, showed an increase in Hb 3 weeks after therapy from 9.6 +/- 0.79 gm%/dl to 
11.11+/- 1.3 gm%/dl in intravenous group and from 9.7+/- 0.5 gm% to 11+/- 1.25 gm% in oral 
group. This was statistically not significant. 
Change in hematocrit
In our study, the mean hematocrit in group A and group B was 30 and 31.4 respectively. 
Post therapy hematocrit assesment after 3 weeks showed an mean hematocrit value of 41.3 and 
36.8 respectively.
P value is 0.0342. This was statistically significant.
The average rise of hematocrit was 11.3 and 5.4 in group A and B respectively, which 
was statistically significant. 
Change in MCV
In our study mean MCV in group A and group B patients  were 68.2 fl  and 66.6 fl 
respectively.  Post  therapy  assesment  showed  an  mean  MCV value  of  83.9  fl  and  74.8  fl 
respectively.
P valuve is 0.0023 which was statistically significant and the average rise in MCV was 
15.7 fl and 8.2 fl in group A and group B respectively.
A  study  by  Mrs.  Khurshid  Shabhir  Raja  et  al,  journal  of  the  Pakistan  Medical 
Association Volume 28, Number 2 july- Dec 2003 showed mean MCV before treatment was 65 
fl, mean MCV 3 weeks post therapy showed 75fl and the mean rise in MCV was 10 fl with p 
value <0.5 which was statistically significant. This study was comparable with our study.
Adverse reactions of the Drugs
In  our  study  side  effects  were  minimal  in  group  A  16% like  headache  2/50  (4%), 
abdominal pain 1/50 (2%), chills and rigors 4/50 (8%) Thrombophlebitis 1/50 (2%), compared 
to more side effects in group B patients like joint pain 32/50 (64%), pain at the injection site 
38/50  (76%),  chills  and  rigors  in  12/50  (24%),  and  abdominal  pain  in  6/50  (12%) of  the 
patients. There were no anaphylactic reactions noted in both groups.
Study by WaliA et al J pak med Assoc. 2002 showed out of 20 patients one patient had 
moderate  abdominal  pain  and  2  had  weakness  and  shivering  and  3  had  phlebitis.  In 
intramuscular  group  majority  complained  of  pain  at  the  injection  site.  This  study  was 
comparable to our study. 
Complaince;
In our study among 50 patients in intravenous group none of the patients discontinued 
the treatment due to adverse effects. 
Study  by  WaliA  et  al  showed  that  none  of  the  patients  in  intravenous  Group 
discontinued the therapy due to any adverse effects. This study was comparable to our study.
In our study among 50 patients in intravenous group 8%(4/50) did not come for follow 
up assesment, where as in intramuscular group 8 patients 8/40 (20%) did not come for follow 
up.
Study by Walia A et al showed that  20% of the patients dropped out from the study out 
of 25 patients due to intolerance. This study was comparable to our study. 
S U M M A R Y
S U M M A R Y
100 patients (50 antenatal patients attending antenatal OPD and 50 postnatal patients 
after delivery) with iron deficiency anemia between September 2007 to September 2008 at 
Government  Rajaji  Hospital  were  selected  according  to  inclusion  and  exclusion  criteria, 
already stated in methodology were taken for this randomised controlled study.
They were allocated into 2 groups of each group A (no. 50; 25 antenatal & 25 postnatal) 
and group B (no 50; 25 antenatal and 25 postnatal)
Group A patients were given intravenous iron sucrose and group B patients were given 
intramuscular iron dextran.
Patients  were  advised  to  attend  our  OPD 3  weeks  after  therapy  and  the  following 
parameters were assesed. 
1. Symptomatic improvement 
2. Hb 
3. hematocrit  
4. MCV.
The results of the study are tabulated, analysed and summarised as follows:-
1. Majority of the patients around 49%  belongs to the age group between 21 – 25 yrs in 
both group A and group B.
2. Almost three fourth of the patients were unbooked (74%). Booked and unbooked  cases 
were equally distributed in both groups.
3. Majority (84%) of the women belongs to class IV socio economic status in both group A 
and group B.
4. Majority  around  68%  were  para  2  and  above,  both  primi  and  multi  were  equally 
distributed in both groups.
5. Most of the patients around 64% were asymptomatic in both group A and group B. 
6. Symptomatic well being observed in all cases (100%) of intravenous group but Only 20 
–  30%  of  the  cases  in  intramuscular  group.  P  value  is  <  0.0001  the  result  was 
statistically significant. 
7. Mean  rise  in  Hb  value  was  2.97  gm/dl  in  intravenous  group  and  1.30  gm/dl  in 
intramuscular group. P value is < 0.001. Which was statistically significant.
8. Target Hb was achieved in 82% of group A and 26% of group B patients, which was 
statistically significant.
9. Average rise in hematocrit value was 11.3 in intravenous group and 5.4 in intramuscular 
group (P value is < 0.0342) which was statistically significant. 
10. Mean rise in MCV was 15.7 fl in group A and 8.2 fl in group B. P value is (< 0.0023) 
which was statistically significant. 
11. The side effects were minimal in group A (16%) compared to 76% in group B. P value 
is < 0.0001, which was statistically significant. 
12. None of the patients in group A discontinued the treatment due to adverse reactions, 
where  as  20%  of  patients  dropped  out  from  the  study  in  group  B  due  to  adverse 
reactions. 
C O N C L U SI O N
CO N C L USIO N
1. Intravenous iron sucrose is highly efficacious in improving Hb, hematocrit values in the 
treatment of iron deficiency anemia in pregnancy and puerperium when compared to 
intramuscular iron dextran.
2. It is well tolerated and safe when compared to intramuscular iron dextran.
3.  complaince  of  the  patient  is  good  in  intravenous  iron  sucrose  when  compared  to 
intramuscular iron dextran.
4. The  side  effects  are  minimal  in  intravenous  group when compared  to  intramuscular 
group.
5. To conclude intravenous iron sucrose therapy is safe,  convenient and more effective 
than intramuscular iron therapy in treatment of iron deficiency anemia.
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P R O F O R M A
PROFORMA
STUDY OF EFFECTIVENESSOF INTRAVENOUS IRON SUCROSE, Vs INTRAMUSCULAR 
IRON DEXTRAN IN IRON DEFICIENCY ANEMIA.
Name : Age :
IP No : Address :
Occupation :
Income :
Socioeconomic Class :
Obstetric table : LMP :
Gravida: EDD :
Para : Weeks of gestation :
Live :
Presenting complaints:
H/o Easy fatiguability / giddiness
H/o Hook worm infestation
H/o Bleeding per vaginum
H/o Hematemesis / malena
H/o Anorexia / indigestion
H/o Multiple pregnancy
H/o Breathlessness
H/o Swelling of legs
H/o Puffiness of face
H/o Iron intolerance
Past H/o
H/o Blood loss in between pregnancy
H/o DM, HT, Asthma, epilepsy, TB
Menstural H/o :
A/M at :
Cycles : Regular Irregular
flow :
Marital H/o:
M /s :
Obstetric History :
Details about previous pregnancy : Yes No
H/o Antepartum Hemorrhage
H/o Postpartum Hemorrhage
H/o Blood Transfusion
Present Pregnancy :
1. Gravida : M/s
Para : LCB :
Live
2. H/o Antepartum Hemorrhage
3. H/o Postpartum Hemorrhage
4. H/o Blood Transfusion
5. H/o Iron and Folic acid intake
General Examination :
Features of Chronic anemia : Yes No
1. Pallor :
2. Glossitis :
3. Facial Puffiness :
4. Koilonochia :
VITALS
PR - Cvs
Bp - Rs
Period of Gestation by clinical examination :
Period Gestation by USG :
Fetal heart rate : 
Investigations :
To confirm iron deficiency anemia :
1. Hb :
2. Urine : Albumin
 Sugar
Deposits
3. Blood : Sugar
Urea
   Serum : Creatinine
5. Peripheral smear :
6. MCV
7. Hematocrit
8. Stool : Ova
Cyst
Iron Requirement :
Dose of intravenous iron sucrose needed & method of therapy :
Dose of intramusuclar iron-dextran needed & method of therapy :
Parameters monitored during therapy :
Adverse effects Yes No
1. Anaphylactic reaction
    (Shivering, Hypotension)
2. Nausea / Vomitting
3. Thrombophlebitis
4. Abdominal Pain
5. Diarrhoea
6. Chills / Rigors 
7. Joint pain
Post therapy Assesment :
Parameters Assesed 3 wks post therapy
1. Symptometic improvement 
2. Hb
3. MCV
4. Hematocrit
A B B R E V ATIO NS
WHO - World Health Organisation
Hb - Hemoglobin
MCV - Mean Corpuscular Volume
MCHC - Mean Corpuscular Hemoglobin Concentration
TIBC - Total Iron Binding Capacity
Fe2+ - Ferrous Iron
Fe3+ - Ferric Iron
SES - Socio Economic Status
F.U - Follow up 
I.V - Intravenous 
I.M - Intramuscular
